Effect of antiretroviral therapy on inflammatory markers of endothelial dysfunction in HIV treatment-Naïve infected patients

José A. Mata-Marín, René Méndez-Cruz, Carla I. Arroyo-Anduiza, Luis A. Mata-Marín, Jesús Gaytán-Martínez, Juan Asbún-Bojalil

Research output: Contribution to journalArticle

5 Citations (Scopus)

Abstract

The aim of this study was to evaluate the effect of antiretroviral therapy on inflammatory markers of endothelial dysfunction in HIV treatment-naïve infected patients. This was a prospective cohort study in HIV treatment-naïve infected patients. The patients were assigned to a untreated group or a treatment group according to the therapeutic strategy received. Patients in the treatment group received efavirenz or lopinavir/ritonavir, each given with zidovudine and lamivudine. HIV RNA, CD4+ cell count, and the levels of hsCRP, sCD40L, sICAM-1, sVCAM-1, and sE-selectin were measured before and 12 weeks after treatment. Fifty patients were enrolled: 13 in the untreated group and 37 in the treatment group; 48 (96%) completed the follow-up. The mean (±SD) age was 33±9 years, and 38 (79%) were men. The median pretreatment CD4+ cell counts were 263cells/ml (IQR 118-341) in the treatment group and 658cells/ml (IQR 475-887) in the untreated group. In the treatment group, the median serum sVCAM-1 and sICAM-1 levels decreased by a small but significant amount (1,400 and 228ng/ml, respectively, P<0.05) from before to after the 12 weeks. These levels did not change in the untreated group. Antiretroviral therapy is associated with a decrease in sVCAM-1 and sICAM-1 levels after 12 weeks of treatment. © 2013 Wiley Periodicals, Inc.
Original languageAmerican English
Pages (from-to)1321-1326
Number of pages1188
JournalJournal of Medical Virology
DOIs
StatePublished - 1 Aug 2013

Fingerprint

HIV
Therapeutics
efavirenz
CD4 Lymphocyte Count
Lopinavir
Selectins
Ritonavir
Lamivudine
Zidovudine
Cohort Studies
Prospective Studies
RNA
Serum

Cite this

Mata-Marín, José A. ; Méndez-Cruz, René ; Arroyo-Anduiza, Carla I. ; Mata-Marín, Luis A. ; Gaytán-Martínez, Jesús ; Asbún-Bojalil, Juan. / Effect of antiretroviral therapy on inflammatory markers of endothelial dysfunction in HIV treatment-Naïve infected patients. In: Journal of Medical Virology. 2013 ; pp. 1321-1326.
@article{6ffd7084e1bb462da3597c946176e966,
title = "Effect of antiretroviral therapy on inflammatory markers of endothelial dysfunction in HIV treatment-Na{\"i}ve infected patients",
abstract = "The aim of this study was to evaluate the effect of antiretroviral therapy on inflammatory markers of endothelial dysfunction in HIV treatment-na{\"i}ve infected patients. This was a prospective cohort study in HIV treatment-na{\"i}ve infected patients. The patients were assigned to a untreated group or a treatment group according to the therapeutic strategy received. Patients in the treatment group received efavirenz or lopinavir/ritonavir, each given with zidovudine and lamivudine. HIV RNA, CD4+ cell count, and the levels of hsCRP, sCD40L, sICAM-1, sVCAM-1, and sE-selectin were measured before and 12 weeks after treatment. Fifty patients were enrolled: 13 in the untreated group and 37 in the treatment group; 48 (96{\%}) completed the follow-up. The mean (±SD) age was 33±9 years, and 38 (79{\%}) were men. The median pretreatment CD4+ cell counts were 263cells/ml (IQR 118-341) in the treatment group and 658cells/ml (IQR 475-887) in the untreated group. In the treatment group, the median serum sVCAM-1 and sICAM-1 levels decreased by a small but significant amount (1,400 and 228ng/ml, respectively, P<0.05) from before to after the 12 weeks. These levels did not change in the untreated group. Antiretroviral therapy is associated with a decrease in sVCAM-1 and sICAM-1 levels after 12 weeks of treatment. {\circledC} 2013 Wiley Periodicals, Inc.",
author = "Mata-Mar{\'i}n, {Jos{\'e} A.} and Ren{\'e} M{\'e}ndez-Cruz and Arroyo-Anduiza, {Carla I.} and Mata-Mar{\'i}n, {Luis A.} and Jes{\'u}s Gayt{\'a}n-Mart{\'i}nez and Juan Asb{\'u}n-Bojalil",
year = "2013",
month = "8",
day = "1",
doi = "10.1002/jmv.23624",
language = "American English",
pages = "1321--1326",
journal = "Journal of Medical Virology",
issn = "0146-6615",
publisher = "Wiley-Liss Inc.",

}

Effect of antiretroviral therapy on inflammatory markers of endothelial dysfunction in HIV treatment-Naïve infected patients. / Mata-Marín, José A.; Méndez-Cruz, René; Arroyo-Anduiza, Carla I.; Mata-Marín, Luis A.; Gaytán-Martínez, Jesús; Asbún-Bojalil, Juan.

In: Journal of Medical Virology, 01.08.2013, p. 1321-1326.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Effect of antiretroviral therapy on inflammatory markers of endothelial dysfunction in HIV treatment-Naïve infected patients

AU - Mata-Marín, José A.

AU - Méndez-Cruz, René

AU - Arroyo-Anduiza, Carla I.

AU - Mata-Marín, Luis A.

AU - Gaytán-Martínez, Jesús

AU - Asbún-Bojalil, Juan

PY - 2013/8/1

Y1 - 2013/8/1

N2 - The aim of this study was to evaluate the effect of antiretroviral therapy on inflammatory markers of endothelial dysfunction in HIV treatment-naïve infected patients. This was a prospective cohort study in HIV treatment-naïve infected patients. The patients were assigned to a untreated group or a treatment group according to the therapeutic strategy received. Patients in the treatment group received efavirenz or lopinavir/ritonavir, each given with zidovudine and lamivudine. HIV RNA, CD4+ cell count, and the levels of hsCRP, sCD40L, sICAM-1, sVCAM-1, and sE-selectin were measured before and 12 weeks after treatment. Fifty patients were enrolled: 13 in the untreated group and 37 in the treatment group; 48 (96%) completed the follow-up. The mean (±SD) age was 33±9 years, and 38 (79%) were men. The median pretreatment CD4+ cell counts were 263cells/ml (IQR 118-341) in the treatment group and 658cells/ml (IQR 475-887) in the untreated group. In the treatment group, the median serum sVCAM-1 and sICAM-1 levels decreased by a small but significant amount (1,400 and 228ng/ml, respectively, P<0.05) from before to after the 12 weeks. These levels did not change in the untreated group. Antiretroviral therapy is associated with a decrease in sVCAM-1 and sICAM-1 levels after 12 weeks of treatment. © 2013 Wiley Periodicals, Inc.

AB - The aim of this study was to evaluate the effect of antiretroviral therapy on inflammatory markers of endothelial dysfunction in HIV treatment-naïve infected patients. This was a prospective cohort study in HIV treatment-naïve infected patients. The patients were assigned to a untreated group or a treatment group according to the therapeutic strategy received. Patients in the treatment group received efavirenz or lopinavir/ritonavir, each given with zidovudine and lamivudine. HIV RNA, CD4+ cell count, and the levels of hsCRP, sCD40L, sICAM-1, sVCAM-1, and sE-selectin were measured before and 12 weeks after treatment. Fifty patients were enrolled: 13 in the untreated group and 37 in the treatment group; 48 (96%) completed the follow-up. The mean (±SD) age was 33±9 years, and 38 (79%) were men. The median pretreatment CD4+ cell counts were 263cells/ml (IQR 118-341) in the treatment group and 658cells/ml (IQR 475-887) in the untreated group. In the treatment group, the median serum sVCAM-1 and sICAM-1 levels decreased by a small but significant amount (1,400 and 228ng/ml, respectively, P<0.05) from before to after the 12 weeks. These levels did not change in the untreated group. Antiretroviral therapy is associated with a decrease in sVCAM-1 and sICAM-1 levels after 12 weeks of treatment. © 2013 Wiley Periodicals, Inc.

UR - https://www.scopus.com/inward/record.uri?partnerID=HzOxMe3b&scp=84879154489&origin=inward

UR - https://www.scopus.com/inward/citedby.uri?partnerID=HzOxMe3b&scp=84879154489&origin=inward

U2 - 10.1002/jmv.23624

DO - 10.1002/jmv.23624

M3 - Article

C2 - 23765771

SP - 1321

EP - 1326

JO - Journal of Medical Virology

JF - Journal of Medical Virology

SN - 0146-6615

ER -